Wyniki wyszukiwania - BazTech

1

LC-MS/MS method assay for simultaneous determination of the pretomanid and pyrazinamide in rat plasma by LC-MS/MS: Assessment of pharmacokinetic drug-drug interaction study

Huang Tao, Wang Li, Wang Fang, Shen Xin, Wang Libin

Acta Chromatographica

|

2024

|

Vol. 36, no. 1

7--13

EN

In the present study, an LC-MS/MS method allowing to quantify pretomanid and pyrazinamide simultaneously in rat plasma was developed. Chromatographic separation was achieved on an Agilent Eclipse plus C18 column (100 mm × 2.1 mm, 3.5 μm; Agilent, USA) and maintained at 30 °C. Multiple reaction monitoring (MRM) using positive-ion ESI mode to monitor ion transitions of m/z 360.1 → m/z 175.1 for pretomanid, m/z 124.1 → m/z 81.0 for pyrazinamide, m/z 172.1 → m/z 128.1 for metronidazole (IS). The calibration curves showed good linear relationships over the concentration range of 50–7,500 ng mL⁻¹ for pretomanid and 500–75,000 ng mL⁻¹ for pyrazinamide. The precision and accuracy were below 15% and within ±15% of the nominal concentrations, respectively. The selectivity, recovery and matrix effect of this method were all within acceptable limits of bioanalytics. The method was applied to the analysis of plasma samples from pharmacokinetic studies in rats. The results show that the main pharmacokinetic parameters of pyrazinamide, namely, T max , t1/2, and AUC(0–t), decreased in the combined group than in the alone group.

2

Development and validation of UPLC-MS/MS method for in vitro quantitative analysis of pyrazinamide in lipid core-shell nanoarchitectonics for improved metabolic stability

Thalla Maharshi, Jala Aishwarya, Borkar Roshan M., Banerjee Subham

Acta Chromatographica

|

2022

|

Vol. 34, no. 3

237--245

EN

Pyrazinamide (PZA), a medication for tuberculosis, has high aqueous solubility and low permeability, undergoes extensive liver metabolism, and exhibits liver toxicity through its metabolites. To avoid this, PZA in lipid core-shell nanoarchitectonics has been formulated to target lymphatic uptake and provide metabolic stability to the incorporated drug. The UPLC-MS/MS method for reliable in vitro quantitative analysis of pyrazinamide (PZA) in lipid core-shell nanoarchitectonics as per ICH guidance was developed and validated using the HILIC column. The developed UPLC-MS/MS method is a simple, precise, accurate, reproducible, and sensitive method for the estimation of PZA in PZA-loaded lipid core-shell nanoarchitectonics for the in vitro determination of % entrapment efficiency, % loading of pyrazinamide, and microsomal stability of lipid core-shell nanoarchitectonics in human liver micro- somes. The % entrapment efficiency was found to be 42.72% (±12.60). Lipid nanoarchitectonics was found to be stable in human liver microsomes, where %QH was found to be 6.20%, that is, low clearance. Thus, this formulation is suitable for preventing PZA-mediated extensive liver metabolism. These findings are relevant for the development of other lipid-mediated, suitable, stable nano- formulations containing PZA through various in vitro methods.

3

Development of validation of RP-HPLC method for simultaneous determination of pyridoxine hydrochloride, isoniazid, pyrazinamide and rifampicin in pharmaceutical formulation

Dhal S. K., Sharma R.

Chemia Analityczna

|

2009

|

Vol. 54, No. 6

1487-1500

EN

A simple, rapid and precise liquid chromatographic method for simultaneous determination of pyridoxine hydrochloride. isomazid, pyrazmamide and rifampicin in a tablet dosage form has been developed Chromatographic analysis was performed on a 250 x 4.6 mm I.D. C|8 column packed with 5 μm-in-size particles applying gradient elution with a mobile phase composed of acetonitrile (A) and 15 mmol L-1 potassium dihydrogen phosphate buffer of pH adjusted to 4.0 J: 0.1 with o-phosphoric acid (B). A:B ratio was 11:89 v/v for the initial 4.5 min. and then it was maintained at 50:50 v/v; the flow rate was 1 mL min-1UV detection was performed at 235 nm. The total run time was 20 mm. Retention times for pyridoxine hydrochloride, isoniazid, pyrazmamide and rifampicin were 3.687, 4.113, 5.041 and 12.829 min, respectively The method was validated with respect to linearity, accuracy, . precision, specificity and sensitivity in accordance with ICH guidelines. Limits of detection were 0.043. 0.063. 0.036 and 0.059 μg mL--1'and limits of quantification were 0.13, 0.19, 0.11 and 0.18 μg ml, ' for pyridoxine hydrochloride, isoniazid, pyrazinamide and rifampicin, respectively. High recovery and low coefficients of variance confirmed the suitability of the method for the simultaneous analysis of the four considered drugs.

PL

Opracowano prostą, szybką i precyzyjną procedurę jednoczesnego oznaczania chlorowodorku pirydoksyny, izoniazydu, pirazynamidu i rifampicyny w tabletkach za pomocą chromatografii cieczowej. Analizę chromatograficzną prowadzono przy użyciu kolumny 250 x 4,6 mm. napełnionej faząC18 o wielkości cząstek wynoszącej 5 urn. Zastosowano gradient fazy ruchomej składającej się z acetonitrylu (A) i buforu w postaci fosforanu dihydropotasowego o stężeniu 15 mmol L-1 i pH = 4 š 0, l ustalonego za pomocą kwasu o-fosforowego (B). Stosunek A i B wynosił 11:89 v/v przez 45 min, następnie był utrzymywany stosunek 50:50 v/v. Przepływ fazy ruchomej wynosił l mL min"1. Całkowity czas rozdzielania składników mieszaniny wynosił 20 min. Detekcję UV prowadzono przy 235 nm. Czasy retencji chlorowodorku pirydoksyny, izoniazydu, pirazynamidu i rifampicyny wynosiły odpowiednio 3.687; 4,113; 5,041 i 12,829 min. Opracowaną procedurę walidowano uwzględniając liniowość, dokładność, precyzję, specyficzność i czułość, zgodnie z zaleceniami Międzynarodowej Konferencji Harmonizacyjnej (ICH). Wykrywalności wynosiły 0.043; 0.063; 0.036 i 0,059μg mL-1a oznaczalności 0,13; 0,19; 0,11 i 0,18 μg mL-1 odpowiednio dla chlorowodorku pirydoksyny, izoniazydu, pirazynamidu i rifampicyny. Wysoki odzysk i małe współczynniki wariancji potwierdziły przydatność metody do jednoczesnej analizy czterech leków.